irinotecan liposome
Onivyde
Pharmaceutical company: Ipsen Biopharmaceuticals
NEW INDICATION & DOSAGE
Metastatic pancreatic adenocarcinoma, as first-line treatment in combination with oxaliplatin, fluorouracil (5-FU), and leucovorin
Adults: 50 mg/m2 IV infusion every 2 weeks. Premedicate with a corticosteroid and an antiemetic 30 minutes before infusion. Administer the drug before oxaliplatin, leucovorin, and 5-FU.
Adjust-a-dose: Refer to the manufacturer's instructions for toxicity-related dosage adjustments.
Released: April 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer
ceftazidime—avibactam sodium
Avycaz
Pharmaceutical company: AbbVie
NEW INDICATION & DOSAGE
Complicated intra-abdominal infections caused by susceptible microorganisms, used in combination with metronidazole
Infants age 29 days to younger than 3 months: 37.5 mg/kg IV every 8 hours for 5 to 14 days.
Infants age 28 days or younger (gestational age 31 weeks and older): 25 mg/kg IV every 8 hours for 5 to 14 days.
Complicated UTI, including pyelonephritis, caused by susceptible microorganisms
Infants age 29 days to younger than 3 months: 37.5 mg/kg IV every 8 hours for 7 to 14 days.
Infants age 28 days or younger (gestational age 31 weeks and older): 25 mg/kg IV every 8 hours for 7 to 14 days.
Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible microorganisms
Infants age 29 days to younger than 3 months: 37.5 mg/kg IV every 8 hours for 7 to 14 days.
Infants age 28 days or younger (gestational age 31 weeks and older): 25 mg/kg IV every 8 hours for 7 to 14 days.
Released: April 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer
omalizumab
Xolair
Pharmaceutical company: Genentech and Novartis
NEW INDICATION & DOSAGE
Reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in patients with IgE-mediated food allergy
Adults and children age 1 year and older: 75 to 600 mg subcut every 2 or 4 weeks. Dose and frequency vary with pretreatment IgE level (international units/mL) and patient weight. (Refer to the manufacturer's instructions.) To be used in conjunction with food allergen avoidance.
Alert: Not indicated for emergency treatment of allergic reactions.
Released: April 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer
osimertinib
Tagrisso
Pharmaceutical company: AstraZeneca
NEW INDICATION & DOSAGE
First-line treatment of patients with locally advanced or metastatic non-small-cell lung cancer (in combination with pemetrexed and platinum-based chemotherapy) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations
Adults: 80 mg PO once daily until disease progression or unacceptable toxicity occurs due to osimertinib.
Released: April 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer